5:41 PM
 | 
Apr 15, 2013
 |  BC Extra  |  Top Story

Supreme Court struggles with gene patents

U.S. Supreme Court Justices appeared to struggle to find middle ground between completely upholding or rejecting U.S. patents issued to Myriad Genetics Inc. (NASDAQ:MYGN) covering the breast cancer 1 early onset (BRCA1) and BRCA2 genes. The court is reviewing a 2-1 decision by the U.S. Court of Appeals for the Federal Circuit that said composition and method...

Read the full 278 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >